Twist Bioscience Corporation

TWST Healthcare Biotechnology

Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.

Revenue
+23.2%
EPS
−264.7%
Free cash flow
−7.23%
Total debt
0.00%

Quarter to June 2026, against a year earlier

129.86 22.92 −15.00%
Market cap
$10.1B
P/E
0.0×
Fwd P/E
−91.4×
Dividend yield
—
F-score
4/9
Altman Z
3.44
Beneish M
−2.30
Dividend safety
n/a

Twist Bioscience Corporation 8-K filed Nov 17, 2023

Period ended Nov 17, 2023 · Filed · accepted 7:32 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov